Renzapride

Research use only, not for human use.

Renzapride (BRL 24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist.Renzapride can be used in the study of constipation-predominant irritable bowel syndrome (C-IBS).

Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study.

Renzapride replaces specific binding of [H3] GR 113808 (a selective 5-HT receptor antagonist) to cloned human 5-HT4 receptors with a Ki value of 115 nM.

Renzapride (BRL 24924) (100 μg i.v.) results in a partial reverse of both the delayed solid and liquid meals emptying.Renzapride (BRL 24924) (0.5-1 mg/kg) significantly increases the rate of emptying of a 51Cr-labeled liquid meal from the murine stomach.Animal Model:Dog (simulating gastroparesis)Dosage:100 μg/kg Administration:i.v.Result:Results in a partial reverse of both the delayed solid and liquid meals emptying.Animal Model: Mice (30-45g) Dosage:0.5-1 mg/kg Administration:p.o.Result:Significantly increase the rate of emptying of a 51Cr-labeled liquid meal from the murine stomach.

——

GPCR/G Protein

5-HT Receptor

5-HT Receptor

——

——

112727-80-7

323.82

C16H22ClN3O2

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (77.20 mM; Ultrasonic )

COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN2CCC[C@@H]1C2

——

(-20℃)

With Ice Pack

≥ 2 years